HDFC Pharma & Healthcare Growth Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹100

HDFC Pharma & Healthcare Growth Direct Plan

NAV
₹16.2840
-2.30%
(25 Apr)
AUM
1,634 Cr
TER
0.87%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
In beta. Send feedback here.
Compare with other fund
1Y
+29.7%
+11.3%
+0.7%
-0.0%
-6.1%
3Y
NA
+30.6%
+30.6%
+32.2%
+29.5%
5Y
NA
+33.9%
+30.9%
+32.8%
+34.5%
ALL
+37.1%
+18.1%
+16.7%
+11.9%
+26.0%
VOL
15.2%
16.4%
19.9%
20.4%
22.8%
TER
0.9%
0.6%
0.9%
0.8%
0.5%
AUM
₹1,634 Cr
₹6,047 Cr
₹1,217 Cr
₹4,789 Cr
₹5,342 Cr
INFO
2.44
1.10
0.84
0.58
1.14
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
HDFC Pharma & Healthcare (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Mar
Top holdings
Sun Pharmaceuticals Industries Ltd
11.8%
Divi's Laboratories Ltd
8.6%
Cipla Ltd
7.2%
Lupin Ltd
5.4%
Max Healthcare Institute Ltd Ordinary Shares
4.9%
Krishna Institute of Medical Sciences Ltd
4.0%
Glenmark Pharmaceuticals Ltd
3.7%
Torrent Pharmaceuticals Ltd
3.6%
Aster DM Healthcare Ltd Ordinary Shares
3.5%
Eris Lifesciences Ltd Registered Shs
3.3%
Top industry exposure
Healthcare
93.7%
Basic Materials
2.0%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹100
Additional lumpsum
₹100
Portfolio turnover
38%
Lock-in period
-
Exit load
• 1% for redemption within 30 days
Fund objective
To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be realized.
Fund manager(s)
Dhruv Muchhal
Nikhil Mathur

FAQs